Yongqi Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yongqi Shen has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Jianlin Chen
Department of Clinical Laboratory, Affiliated Liutie Central Hospital of Guangxi Medical University, Guangxi, China
3 shared publicationsDi Zhang
Department of Clinical Laboratory, The Third Xiangya Hospital of Central South University, Hunan, China
2 shared publicationsHaihua Long
Affiliated Liutie Central Hospital of Guangxi Medical University, Liuzhou, China
2 shared publicationsHaoming Shen
Department of Clinical Laboratory, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan, China
2 shared publicationsSha He
Department of Hepatobiliary Surgery, Affiliated Liutie Central Hospital of Guangxi Medical University, Guangxi, China
2 shared publicationsWenjie Huang
Department of Clinical Laboratory, Affiliated Liutie Central Hospital of Guangxi Medical University, Guangxi, China
2 shared publications
Latest Publications
- Open Access
- 7 November 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1576458
Autologous platelet-rich gel versus vitamin B12 for the treatment of grade III-IV acute radiation dermatitis in malignant tumor patients undergoing radiotherapy: an open-label randomized controlled clinical trial
Background: Acute radiation-induced dermatitis (ARD) remains the most prevalent adverse event associated with radiotherapy;however, effective management options remain limited.This study was designed to evaluate the efficacy and safety of autologous platelet-rich gel(APRG) versus vitamin B12 in the treatment of grade III to IV acute radiation dermatitis in patients with malignant tumors. Materials and methods: 40 patients diagnosed with Grade III–IV acute ARD were randomly assigned in a 1:1 ratio to either the APRG group (n = 20) or the vitamin B12 group (n = 20). All patients received wound cleansing prior to intervention. In the APRG group, the prepared gel was sprayed onto the wound surface, which was then covered with sterile Vaseline gauze and a secondary dressing for 2 to 3 days. In the vitamin B12 group, wounds were treated with a wet compress consisting of 5 mg vitamin B12 dissolved in 100 mL normal saline, applied for 30 minutes per session, three times daily. ARD severity was graded according to the RTOG criteria, and adverse events (AEs) were assessed using CTCAE v4.0 by trained oncologists. The numerical rating scale (NRS) for the topical pain and Quality of Life Instrument for Cancer Patients in China (QOL-CCC) were subjectively reported by patients. Results: The APRG group demonstrated a significant shortening in the median healing time for ARD compared to the Vitamin B12 group (3.0 days, IQR: 2.0-4.0 vs. 8.0 days, IQR: 5.0-12.0; p < 0.001). Furthermore, patients treated with APRG reported consistently and significantly lower pain levels from day 2 through day 7 post-therapy (F = 24.288, P < 0.001). Superior improvements in five key quality-of-life domains—sleep, mental state, fatigue, activities of daily living, and appetite—were also observed in the APRG group (all P < 0.05). Critically, no treatment-related adverse events were recorded in the APRG group during the follow-up period. Conclusion: Our findings establish APRG as a superior and transformative intervention over Vitamin B12, demonstrating significant efficacy in accelerating wound healing, reducing pain, improving patient quality of life, and maintaining a safe treatment profile. Registration Details: https://www.chictr.org.cn/showproj.html?proj=222262 , identifier ChiCTR2400081656.
- 7 November 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1576458
Open AccessAutologous platelet-rich gel versus vitamin B12 for the treatment of grade III-IV acute radiation dermatitis in malignant tumor patients undergoing radiotherapy: an open-label randomized controlled clinical trial
Background: Acute radiation-induced dermatitis (ARD) remains the most prevalent adverse event associated with radiotherapy;however, effective management options remain limited.This study was designed to evaluate the efficacy and safety of autologous platelet-rich gel(APRG) versus vitamin B12 in the treatment of grade III to IV acute radiation dermatitis in patients with malignant tumors. Materials and methods: 40 patients diagnosed with Grade III–IV acute ARD were randomly assigned in a 1:1 ratio to either the APRG group (n = 20) or the vitamin B12 group (n = 20). All patients received wound cleansing prior to intervention. In the APRG group, the prepared gel was sprayed onto the wound surface, which was then covered with sterile Vaseline gauze and a secondary dressing for 2 to 3 days. In the vitamin B12 group, wounds were treated with a wet compress consisting of 5 mg vitamin B12 dissolved in 100 mL normal saline, applied for 30 minutes per session, three times daily. ARD severity was graded according to the RTOG criteria, and adverse events (AEs) were assessed using CTCAE v4.0 by trained oncologists. The numerical rating scale (NRS) for the topical pain and Quality of Life Instrument for Cancer Patients in China (QOL-CCC) were subjectively reported by patients. Results: The APRG group demonstrated a significant shortening in the median healing time for ARD compared to the Vitamin B12 group (3.0 days, IQR: 2.0-4.0 vs. 8.0 days, IQR: 5.0-12.0; p < 0.001). Furthermore, patients treated with APRG reported consistently and significantly lower pain levels from day 2 through day 7 post-therapy (F = 24.288, P < 0.001). Superior improvements in five key quality-of-life domains—sleep, mental state, fatigue, activities of daily living, and appetite—were also observed in the APRG group (all P < 0.05). Critically, no treatment-related adverse events were recorded in the APRG group during the follow-up period. Conclusion: Our findings establish APRG as a superior and transformative intervention over Vitamin B12, demonstrating significant efficacy in accelerating wound healing, reducing pain, improving patient quality of life, and maintaining a safe treatment profile. Registration Details: https://www.chictr.org.cn/showproj.html?proj=222262 , identifier ChiCTR2400081656.
- Open Access
Validation of CDC45 as a novel biomarker for diagnosis and prognosis of gastric cancer
Background: Cell division cycle protein 45 (CDC45) has been demonstrated to play vital roles in the progression of various malignancies. However, the clinical significance of CDC45 in gastric cancer (GC) remains unreported. Method: In this study, we employed the TCGA database and the TCGA & GTEx dataset to compare the mRNA expression levels of CDC45 between gastric cancer tissues and adjacent or normal tissues (p < 0.05 was considered statistically significant), which was further validated in multiple datasets including GSE13911, GSE29272, GSE118916, GSE66229, as well as RT-qPCR. Furthermore, we harnessed the Human Protein Atlas (HPA) to evaluate the protein expression of CDC45, which was subsequently verified through immunohistochemistry (IHC). To ascertain the diagnostic utility of CDC45, receiver operating characteristic (ROC) curves and the area under the ROC curve (AUC) were calculated in TCGA database, and further validated it in TCGA & GTEx and GSE66229 datasets. The Kaplan–Meier method was used to reveal the prognostic importance of CDC45 in The Cancer Genome Atlas (TCGA) database and authenticated through the GSE66229, GSE84433, and GSE84437 datasets. Through cBioPortal, we identified co-expressed genes of CDC45, and pursued enrichment analysis. Additionally, we availed gene set enrichment analysis (GSEA) to annotate the biological functions of CDC45. Results: Differential expression analysis revealed that CDC45 was significantly upregulated at both the mRNA and protein levels in GC (all p < 0.05). Remarkably, CDC45 emerged as a promising prognostic indicator and a novel diagnostic biomarker for GC. In a comprehensive the drug susceptibility analysis, we found that patients with high expression of CDC45 had high sensitivity to various chemotherapeutic agents, among which 5-fluorouracil, docetaxel, cisplatin, and elesclomol were most evident. Furthermore, our findings suggested a plausible association between CDC45 and immune cell infiltration. Enrichment analysis revealed that CDC45 and its associated genes may play crucial roles in muscle biofunction, whereas GSEA demonstrated significant enrichment of gene sets pertaining to G protein-coupled receptor ligand binding and G alpha (i) signaling events. Conclusion: Our study elucidates that upregulation of CDC45 is intricately associated with immune cell infiltration and holds promising potential as a favorable prognostic marker and a novel diagnostic biomarker for GC.
Open AccessValidation of CDC45 as a novel biomarker for diagnosis and prognosis of gastric cancer
Background: Cell division cycle protein 45 (CDC45) has been demonstrated to play vital roles in the progression of various malignancies. However, the clinical significance of CDC45 in gastric cancer (GC) remains unreported. Method: In this study, we employed the TCGA database and the TCGA & GTEx dataset to compare the mRNA expression levels of CDC45 between gastric cancer tissues and adjacent or normal tissues (p < 0.05 was considered statistically significant), which was further validated in multiple datasets including GSE13911, GSE29272, GSE118916, GSE66229, as well as RT-qPCR. Furthermore, we harnessed the Human Protein Atlas (HPA) to evaluate the protein expression of CDC45, which was subsequently verified through immunohistochemistry (IHC). To ascertain the diagnostic utility of CDC45, receiver operating characteristic (ROC) curves and the area under the ROC curve (AUC) were calculated in TCGA database, and further validated it in TCGA & GTEx and GSE66229 datasets. The Kaplan–Meier method was used to reveal the prognostic importance of CDC45 in The Cancer Genome Atlas (TCGA) database and authenticated through the GSE66229, GSE84433, and GSE84437 datasets. Through cBioPortal, we identified co-expressed genes of CDC45, and pursued enrichment analysis. Additionally, we availed gene set enrichment analysis (GSEA) to annotate the biological functions of CDC45. Results: Differential expression analysis revealed that CDC45 was significantly upregulated at both the mRNA and protein levels in GC (all p < 0.05). Remarkably, CDC45 emerged as a promising prognostic indicator and a novel diagnostic biomarker for GC. In a comprehensive the drug susceptibility analysis, we found that patients with high expression of CDC45 had high sensitivity to various chemotherapeutic agents, among which 5-fluorouracil, docetaxel, cisplatin, and elesclomol were most evident. Furthermore, our findings suggested a plausible association between CDC45 and immune cell infiltration. Enrichment analysis revealed that CDC45 and its associated genes may play crucial roles in muscle biofunction, whereas GSEA demonstrated significant enrichment of gene sets pertaining to G protein-coupled receptor ligand binding and G alpha (i) signaling events. Conclusion: Our study elucidates that upregulation of CDC45 is intricately associated with immune cell infiltration and holds promising potential as a favorable prognostic marker and a novel diagnostic biomarker for GC.
- Open Access
- 21 February 2022
- Published by Springer Nature in Cell Death Discovery
- Vol. 8 (1) , 1
Correction: Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance
- 21 February 2022
- Published by Springer Nature in Cell Death Discovery
- Vol. 8 (1) , 1
Open AccessCorrection: Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance
- Open Access
- 18 November 2021
- Published by Springer Nature in Cell Death Discovery
- Vol. 7 (1) , 1-12
Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance
Lenvatinib is the first target drug approved for advanced hepatocellular carcinoma (HCC). However, the development of drug resistance is common, and the mechanisms of lenvatinib resistance and resistant targets in HCC are poorly understood. By using CRISPR/Cas9 library screening, we screened out two key resistance genes, neurofibromin 1(NF1), and dual specificity phosphatase 9 (DUSP9), as critical drivers for lenvatinib resistance in HCC. With RNAi knockdown and CRISPR/Cas9 knockout models, we further clarified the mechanisms by which NF1 loss reactivates the PI3K/AKT and MAPK/ERK signaling pathways, while DUSP9 loss activates the MAPK/ERK signaling pathways, thereby inactivating FOXO3, followed by degradation of FOXO3, finally induced lenvatinib resistance. We also screened out trametinib, a small molecule pathway inhibitor for MEK, that can be used to reverse resistance induced by NF1 and DUSP9 loss in HCC cells. Trametinib was still able to halt HCC growth even when NF1 was knocked out in mice. Collectively, the findings indicate that NF1 and DUSP9 takes critical role in lenvatinib resistance and may be novel specific targets and predictive markers for lenvatinib resistance in HCC.
- 18 November 2021
- Published by Springer Nature in Cell Death Discovery
- Vol. 7 (1) , 1-12
Open AccessGenome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance
Lenvatinib is the first target drug approved for advanced hepatocellular carcinoma (HCC). However, the development of drug resistance is common, and the mechanisms of lenvatinib resistance and resistant targets in HCC are poorly understood. By using CRISPR/Cas9 library screening, we screened out two key resistance genes, neurofibromin 1(NF1), and dual specificity phosphatase 9 (DUSP9), as critical drivers for lenvatinib resistance in HCC. With RNAi knockdown and CRISPR/Cas9 knockout models, we further clarified the mechanisms by which NF1 loss reactivates the PI3K/AKT and MAPK/ERK signaling pathways, while DUSP9 loss activates the MAPK/ERK signaling pathways, thereby inactivating FOXO3, followed by degradation of FOXO3, finally induced lenvatinib resistance. We also screened out trametinib, a small molecule pathway inhibitor for MEK, that can be used to reverse resistance induced by NF1 and DUSP9 loss in HCC cells. Trametinib was still able to halt HCC growth even when NF1 was knocked out in mice. Collectively, the findings indicate that NF1 and DUSP9 takes critical role in lenvatinib resistance and may be novel specific targets and predictive markers for lenvatinib resistance in HCC.
- Open Access
- 18 September 2020
- Published by Spandidos Publications in Oncology Letters
- Vol. 20 (5) , 1
Diagnostic value and clinical significance of circulating miR‑650 and CA211 in detecting of gastric carcinoma
The present study determined the levels of plasma biomarkers in patients with gastric carcinoma (GC) and investigated their clinical significance and diagnostic value. Between April 2014 and December 2018, 90 patients with GC, 90 patients with precancerous lesions (Pre) and 45 healthy controls (NC) were recruited from the Affiliated Liutie Central Hospital of Guangxi Medical University. Five markers were measured: microRNA‑650 (miRNA‑650; using reverse transcription‑quantitative polymerase chain reaction), and carcinoembryonic antigen (CEA), carbohydrate antigen (CA)125, CA211 and CA50 using electrochemiluminescence. Circulating markers were all upregulated in patients with GC (P<0.05), and CA211 and CA50 were significantly increased in patients with Pre. The miRNA‑650 and CA211 had an area under the curve (AUC) of 0.700 (moderate) and 0.866 (high), respectively, in the diagnosis of GC. Differentiation of GC from Pre yielded an AUC of 0.665 (low) and 0.708 (moderate), respectively. The combination model of miRNA‑650 and CA211 showed an appropriate value of AUC (0.887) to discriminate the GC patients from the healthy subjects with a sensitivity and specificity of 82.5 and 97.7%. Additionally, differentiating GC from Pre yielded an AUC of 0.767 with a sensitivity of 57.1% and a specificity of 95%, respectively. In terms of clinicopathological features, the expression of miRNA‑650 and CA211 in plasma was not associated with the patients' age, sex, Tumor‑Node‑Metastasis stage, or histological type. In conclusion, plasma miRNA‑650 and CA211 is a promising and powerful non‑invasive marker for the detection of GC.
- 18 September 2020
- Published by Spandidos Publications in Oncology Letters
- Vol. 20 (5) , 1
Open AccessDiagnostic value and clinical significance of circulating miR‑650 and CA211 in detecting of gastric carcinoma
The present study determined the levels of plasma biomarkers in patients with gastric carcinoma (GC) and investigated their clinical significance and diagnostic value. Between April 2014 and December 2018, 90 patients with GC, 90 patients with precancerous lesions (Pre) and 45 healthy controls (NC) were recruited from the Affiliated Liutie Central Hospital of Guangxi Medical University. Five markers were measured: microRNA‑650 (miRNA‑650; using reverse transcription‑quantitative polymerase chain reaction), and carcinoembryonic antigen (CEA), carbohydrate antigen (CA)125, CA211 and CA50 using electrochemiluminescence. Circulating markers were all upregulated in patients with GC (P<0.05), and CA211 and CA50 were significantly increased in patients with Pre. The miRNA‑650 and CA211 had an area under the curve (AUC) of 0.700 (moderate) and 0.866 (high), respectively, in the diagnosis of GC. Differentiation of GC from Pre yielded an AUC of 0.665 (low) and 0.708 (moderate), respectively. The combination model of miRNA‑650 and CA211 showed an appropriate value of AUC (0.887) to discriminate the GC patients from the healthy subjects with a sensitivity and specificity of 82.5 and 97.7%. Additionally, differentiating GC from Pre yielded an AUC of 0.767 with a sensitivity of 57.1% and a specificity of 95%, respectively. In terms of clinicopathological features, the expression of miRNA‑650 and CA211 in plasma was not associated with the patients' age, sex, Tumor‑Node‑Metastasis stage, or histological type. In conclusion, plasma miRNA‑650 and CA211 is a promising and powerful non‑invasive marker for the detection of GC.
- Open Access
- 1 October 2019
- Published by Springer Nature in Cancer Cell International
- Vol. 19 (1) , 1-8
PGM5 is a promising biomarker and may predict the prognosis of colorectal cancer patients
Background: Phosphoglucomutase (PGM), a key enzyme in the metabolism of glucose-1-phosphate and glucose-6-phosphate, has been found to be associated with proliferation, invasion, and metastasis of cancer. However, the expression and function of PGM5 in colorectal cancer (CRC) remains unknown.Methods: We tested PGM5 mRNA and protein expression levels in 79 CRC tissue and their matched adjacent tissue samples by qRT-PCR and immunohistochemistry, respectively. Overall survival (OS) was estimated with the Kaplan–Meier method and compared between groups with the log-rank test. We performed multivariable Cox regression analyses to identify factors associated with CRC risk. The cell proliferation, migration and invasion abilities of CRC cells were detected by using CCK-8, Transwell migration and invasion assays, respectively.Results: The PGM5 protein levels expression in CRC tissues were significantly lower than those in the adjacent tissues (t = 5.035,P < 0.001), and Kaplan–Meier analysis indicated that low PGM5 expression were significantly associated with poor overall survival (P = 0.0069). Univariate and multivariate analyses demonstrated that PGM5 was an independent risk factor for overall survival (hazard ratio = 0.3951,P = 0.014). PGM5 overexpression significantly inhibited the proliferation, invasion and migration abilities of CRC cells. On the contrary, knockdown of PGM5 promotes the invasion and migration of CRC cells.Conclusions: PMG5 regulates proliferation, invasion, and migration in the CRC and decreased PGM5 is associated with poor prognosis. Therefore, PGM5 is a promising biomarker in CRC and decreased PGM5 may predict poor overall survival in patients with CRC.
- 1 October 2019
- Published by Springer Nature in Cancer Cell International
- Vol. 19 (1) , 1-8
Open AccessPGM5 is a promising biomarker and may predict the prognosis of colorectal cancer patients
Background: Phosphoglucomutase (PGM), a key enzyme in the metabolism of glucose-1-phosphate and glucose-6-phosphate, has been found to be associated with proliferation, invasion, and metastasis of cancer. However, the expression and function of PGM5 in colorectal cancer (CRC) remains unknown.Methods: We tested PGM5 mRNA and protein expression levels in 79 CRC tissue and their matched adjacent tissue samples by qRT-PCR and immunohistochemistry, respectively. Overall survival (OS) was estimated with the Kaplan–Meier method and compared between groups with the log-rank test. We performed multivariable Cox regression analyses to identify factors associated with CRC risk. The cell proliferation, migration and invasion abilities of CRC cells were detected by using CCK-8, Transwell migration and invasion assays, respectively.Results: The PGM5 protein levels expression in CRC tissues were significantly lower than those in the adjacent tissues (t = 5.035,P < 0.001), and Kaplan–Meier analysis indicated that low PGM5 expression were significantly associated with poor overall survival (P = 0.0069). Univariate and multivariate analyses demonstrated that PGM5 was an independent risk factor for overall survival (hazard ratio = 0.3951,P = 0.014). PGM5 overexpression significantly inhibited the proliferation, invasion and migration abilities of CRC cells. On the contrary, knockdown of PGM5 promotes the invasion and migration of CRC cells.Conclusions: PMG5 regulates proliferation, invasion, and migration in the CRC and decreased PGM5 is associated with poor prognosis. Therefore, PGM5 is a promising biomarker in CRC and decreased PGM5 may predict poor overall survival in patients with CRC.
- Open Access
- 1 August 2011
- Published by Oxford University Press (OUP) in Laboratory Medicine
- Vol. 42 (8) , 478-481
The Effects of Storage Time of Colorectal Cancer Tissue on the Detection of K-rasGene
Background:. The storage times of formalin-fixed paraffin embedded (FFPE) colorectal cancer (CRC) tissues can differ. In this study we investigated the
- 1 August 2011
- Published by Oxford University Press (OUP) in Laboratory Medicine
- Vol. 42 (8) , 478-481
Open AccessThe Effects of Storage Time of Colorectal Cancer Tissue on the Detection of K-rasGene
Background:. The storage times of formalin-fixed paraffin embedded (FFPE) colorectal cancer (CRC) tissues can differ. In this study we investigated the